Clinical Trial

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

Name: TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients — clinical trial record (NCT07489755)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

A Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs

Trial Details

NCT Number	NCT07489755
Lead Sponsor	Shenzhen TargetRx Co., Ltd.
Conditions	Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase
Enrollment	180 participants
Start Date	2026-04-01
Primary Completion	2030-05-01 (estimated)
Study Completion	2031-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-24